As the plot thickens around the trigger for Aveo’s equity raise, the EU regulator considers pulling the group's renal cancer drug from the market.
A study of a liquid biopsy and another looking at tumour mutational burden testing give early indications of Foundation’s approval strategy.
Questions about Akebia's disclosure of liver toxicity in a trial raise a red flag over vadadustat, the company's experimental anaemia treatment.
Encouraging early data from an academic trial of Clovis's Rubraca raise hopes that Parps could emerge as a more tolerable maintenance therapy for some pancreatic…
A patient death notwithstanding, Chi-Med reckons results from the Tatton study justify its US registration strategy.
UK group bets billions on an HER2 project slated for late-line patients and those with lower expression of the target protein.
Astrazeneca gets one over on Sanofi and Lexicon with European approval for Forxiga. US regulators might not be so forgiving.
Pfizer/Merck KGaA scrap a pivotal trial, partly because it tested Bavencio against what is no longer the relevant standard of care.
Business development decisions have started the clock on a financial time bomb set to go off within the next three months.